Biotech Values

[DewDiligence]

It is also interesting that Sanofi was explicit in asserting their expectation for further erosion in the coming quarters as a result of the new generic competition.

SNY does not expect further erosion in Lovenox market share and any statement to that effect is a misunderstanding. SNY merely wanted to call attention to the fact that, in 3Q10, generic competition was on the market for less than the full quarter.